Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2014 (2014), Article ID 123105, 6 pages
http://dx.doi.org/10.1155/2014/123105
Clinical Study

Urate Lowering Therapy with Febuxostat in Daily Practice—A Multicentre, Open-Label, Prospective Observational Study

1Department of Rheumatology, University Clinic “Carl Gustav Carus”, Technical University Dresden, Fetscherstraße 74, 01307 Dresden, Germany
2Rheumatology, Rehaklinik am Kurpark, Kurhausstraße 9, 97688 Bad Kissingen, Germany
3Sybelstraße 42, 10629 Berlin, Germany

Received 7 February 2014; Revised 23 July 2014; Accepted 20 August 2014; Published 3 September 2014

Academic Editor: Ruben Burgos-Vargas

Copyright © 2014 Anne-Kathrin Tausche et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Annemans, E. Spaepen, M. Gaskin et al., “Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005,” Annals of the Rheumatic Diseases, vol. 67, no. 7, pp. 960–966, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. E. U. Smith, C. Díaz-Torné, F. Perez-Ruiz, and L. M. March, “Epidemiology of gout: an update,” Best Practice & Research Clinical Rheumatology, vol. 24, no. 6, pp. 811–827, 2010. View at Google Scholar
  3. M. Doherty, “New insights into the epidemiology of gout,” Rheumatology, vol. 48, no. 2, pp. ii2–ii8, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Perez-Ruiz, “Treating to target: a strategy to cure gout,” Rheumatology, vol. 48, no. 2, pp. ii9–ii14, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. A. K. Tausche, B. Manger, U. Müller-Ladner, and B. Schmidt, “Gout as a systemic disease. Manifestations, complications and comorbidities of hyperuricaemia,” Zeitschrift für Rheumaforschung, vol. 71, no. 3, pp. 224–230, 2012. View at Google Scholar
  6. W. Zhang, M. Doherty, T. Bardin et al., “EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies including therapeutics (ESCISIT),” Annals of the Rheumatic Diseases, vol. 65, no. 10, pp. 1312–1324, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. K. Tausche, T. L. Jansen, H. E. Schröder, S. R. Bornstein, M. Aringer, and U. Müller-Ladner, “Gout—current diagnosis and treatment,” Deutsches Ärzteblatt international, vol. 106, no. 34-35, pp. 549–555, 2009. View at Google Scholar
  8. K. M. Jordan, J. S. Cameron, M. Snaith et al., “British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout,” Rheumatology, vol. 46, no. 8, pp. 1372–1374, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Khanna, J. D. Fitzgerald, P. P. Khanna et al., “American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia,” Arthritis Care & Research, vol. 64, no. 10, pp. 1431–1446, 2012. View at Google Scholar
  10. D. Khanna, P. P. Khanna, J. D. Fitzgerald et al., “2012 American college of rheumatology guidelines for management of gout. part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis,” Arthritis Care and Research, vol. 64, no. 10, pp. 1447–1461, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. “Summary of product characteristics febuxostat,” http://www.ema.europa.eu.
  12. N. L. Edwards, “Febuxostat: a new treatment for hyperuricaemia in gout,” Rheumatology, vol. 48, no. 2, pp. ii15–ii19, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. A. Becker, H. R. Schumacher Jr., R. L. Wortmann et al., “Febuxostat compared with allopurinol in patients with hyperuricemia and gout,” The New England Journal of Medicine, vol. 353, no. 23, pp. 2450–2461, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Doherty, T. L. Jansen, G. Nuki et al., “Gout: why is this curable disease so seldom cured?” Annals of the Rheumatic Diseases, vol. 71, no. 11, pp. 1765–1770, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. A. K. Tausche, G. Nuki, F. Perez-Ruiz et al., “Chronic gout in Europe in 2010: clinical profile of 1380 patients in the UK, Germany, France, Italy and Spain on urate lowering therapy,” Zeitschrift für Rheumatologie, vol. 71, article 50, 2012. View at Google Scholar
  16. H. R. Schumacher Jr., M. A. Becker, E. Lloyd, P. A. MacDonald, and C. Lademacher, “Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study,” Rheumatology, vol. 48, no. 2, pp. 188–194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Whelton, P. A. MacDonald, S. Chefo, and L. Gunawardhana, “Preservation of renal function during gout treatment with febuxostat: a quantitative study,” Postgraduate Medicine, vol. 125, no. 1, pp. 106–114, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Halevy, P.-D. Ghislain, M. Mockenhaupt et al., “Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel,” Journal of the American Academy of Dermatology, vol. 58, no. 1, pp. 25–32, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Bardin and G. Desideri, “How to manage patients with gout,” Current Medical Research and Opinion, vol. 29, no. 3, pp. 17–24, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Terkeltaub, “Update on gout: new therapeutic strategies and options,” Nature Reviews Rheumatology, vol. 6, no. 1, pp. 30–38, 2010. View at Publisher · View at Google Scholar · View at Scopus